Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study

Ann Surg Oncol. 2018 May;25(5):1440-1447. doi: 10.1245/s10434-018-6391-z. Epub 2018 Mar 12.

Abstract

Background: Western multicenter studies on distal pancreatectomy with celiac axis resection (DP-CAR), also known as the Appleby procedure, for locally advanced pancreatic cancer are lacking. We aimed to study overall survival, morbidity, mortality and the impact of preoperative hepatic artery embolization (PHAE).

Methods: Retrospective cohort study within the European-African Hepato-Pancreato-Biliary-Association, on DP-CAR between 1-1-2000 and 6-1-2016. Primary endpoint was overall survival. Secondary endpoints were radicality (R0-resection), 90-day mortality, major morbidity, and pancreatic fistulae (grade B/C).

Results: We included 68 patients from 20 hospitals in 12 countries. Postoperatively, 53% of patients had R0-resection, 25% major morbidity, 21% an ISGPS grade B/C pancreatic fistula, and 16% mortality. In total, 82% received (neo-)adjuvant chemotherapy and median overall survival in 62 patients with pancreatic ductal adenocarcinoma patients was 18 months (CI 10-37). We observed no impact of PHAE on ischemic complications.

Conclusions: DP-CAR combined with chemotherapy for locally advanced pancreatic cancer is associated with acceptable overall survival. The 90-day mortality is too high and should be reduced. Future studies should investigate to what extent increasing surgical volume or better patient selection can improve outcomes.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Pancreatic Ductal / therapy*
  • Celiac Artery / surgery
  • Chemoradiotherapy, Adjuvant
  • Chemotherapy, Adjuvant
  • Embolization, Therapeutic*
  • Europe / epidemiology
  • Female
  • Hepatic Artery
  • Hospitals, High-Volume / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Pancreatectomy / adverse effects*
  • Pancreatectomy / methods
  • Pancreatectomy / mortality
  • Pancreatic Neoplasms / therapy*
  • Postoperative Complications / etiology*
  • Postoperative Complications / mortality
  • Postoperative Complications / surgery
  • Preoperative Period
  • Reoperation
  • Retrospective Studies
  • Survival Rate

Substances

  • Antineoplastic Agents